Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
ATMARINOMED6
Fri, 11.10.2024
Marinomed Biotech AG
Korneuburg, Austria, 11. October 2024 - Marinomed Biotech AG (the "Company") announces that, after a thorough review of existing offers, the Management Board today decided to enter contract negotiations for the sale of the Carragelose portfolio in the form of an asset deal. The Company selected the potential buyer based on a combination of favorabl [ … ]
Wed, 18.09.2024
Marinomed Biotech AG
Korneuburg, Austria, 18. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company's share capital by EUR 154,053 to EUR 1,694,583 by issuing 154,053 new no-par value bearer shares against cash contributions. The new shares will be issued from the authorized capital 2024 and [ … ]
Wed, 18.09.2024
Marinomed Biotech AG
Korneuburg, Austria, 18. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company's share capital by EUR 154,053 to EUR 1,694,583 by issuing 154,053 new no-par value bearer shares against cash contributions. The new shares will be issued from the authorized capital 2024 and [ … ]
Sun, 15.09.2024
Marinomed Biotech AG
Korneuburg, Austria, 15. September 2024 – Marinomed Biotech AG (the “Company”) announces that today the Management Board decided to set a price range of EUR 4.90 to a maximum of EUR 5.20 per new share for a potential capital increase of up to 154,053 new shares to be issued under the Authorized Capital 2024 and subject to the direct exclusion of th [ … ]
Sun, 15.09.2024
Marinomed Biotech AG
Korneuburg, Austria, 15. September 2024 – Marinomed Biotech AG (the “Company”) announces that today the Management Board decided to set a price range of EUR 4.90 to a maximum of EUR 5.20 per new share for a potential capital increase of up to 154,053 new shares to be issued under the Authorized Capital 2024 and subject to the direct exclusion of th [ … ]
Mon, 02.09.2024
Marinomed Biotech AG
Korneuburg, Austria, 02. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board decided today to evaluate a capital increase of up to 154,053 new shares to be issued from the Authorized Capital 2024, subject to the direct exclusion of statutory subscription rights of existing shareholders, to finance the ongoing c [ … ]
Wed, 14.08.2024
Marinomed Biotech AG
Korneuburg, Austria, 14. August 2024 – Marinomed Biotech AG (VSE:MARI) announces that on August 14, 2024, the Regional Court of Korneuburg opened restructuring proceedings without self-administration at the request of Marinomed Biotech AG. The Company expects trading of Marinomed shares to resume soon and a switch to the standard market continuous [ … ]
Tue, 13.08.2024
Marinomed Biotech AG
Korneuburg, Austria, 13. August 2024 – Marinomed Biotech AG (VSE:MARI) announces to apply for the initiation of court restructuring proceedings. The aim is to carry out restructuring proceedings without self-administration.
As a result of the inability to raise funds required at short notice to secure the Company’s liquidity, insolvency is imminent [ … ]
Mon, 18.12.2023
Marinomed Biotech AG
Korneuburg, Austria, 18 December 2023 – Marinomed Biotech AG (VSE:MARI) announces that the Company considers strategic options for its Carragelose business and has mandated an external advisor. A structured process was initiated, in which Marinomed and the advisor will start engaging with potential partners.
The Company is continuously evaluating [ … ]